

## IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020

SOUTH SAN FRANCISCO, Calif., Jan. 6, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

(NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2020 at 5:00 p.m. PT (8:00 p.m. ET).

---

### **About IDEAYA Biosciences**

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.

---

### **Forward-Looking Statements**

This press release contains forward-looking statements, including, but not limited to, statements related to expected presentation of company information and timing thereof at the J.P. Morgan Healthcare Conference. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with

manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 13, 2019 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

---

View original content to download multimedia:<http://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-on-wednesday-january-15-2020-300980719.html>

SOURCE IDEAYA Biosciences, Inc.

For further information: Investor and Media Contact, IDEAYA Biosciences, Inc., Paul Stone, Chief Financial Officer, [pstone@ideayabio.com](mailto:pstone@ideayabio.com)

---

<https://media.ideayabio.com/2020-01-06-IDEAYA-Biosciences-to-Present-at-the-38th-Annual-J-P-Morgan-Healthcare-Conference-on-Wednesday-January-15-2020>